224 related articles for article (PubMed ID: 23369893)
21. Overview of the rationale for immunomodulating therapies in multiple sclerosis.
Lisak RP
Neurology; 1988 Jul; 38(7 Suppl 2):5-8. PubMed ID: 3290714
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional targeting of DCs with lentiviral vectors induces antigen-specific tolerance in a mouse model of multiple sclerosis.
de Andrade Pereira B; Fraefel C; Hilbe M; Ackermann M; Dresch C
Gene Ther; 2013 May; 20(5):556-66. PubMed ID: 22951454
[TBL] [Abstract][Full Text] [Related]
23. Vaccination with autologous dendritic cells: from experimental autoimmune encephalomyelitis to multiple sclerosis.
Link H; Huang YM; Masterman T; Xiao BG
J Neuroimmunol; 2001 Mar; 114(1-2):1-7. PubMed ID: 11240009
[TBL] [Abstract][Full Text] [Related]
24. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
25. Cancer vaccines for established cancer: how to make them better?
Andrews DM; Maraskovsky E; Smyth MJ
Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cells: controllers of the immune system and a new promise for immunotherapy.
Banchereau J; Fay J; Pascual V; Palucka AK
Novartis Found Symp; 2003; 252():226-35; discussion 235-8, 257-67. PubMed ID: 14609222
[TBL] [Abstract][Full Text] [Related]
27. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
H Yi D; Appel S
Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
[TBL] [Abstract][Full Text] [Related]
28. Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy.
Berghella AM; Totaro R; Pellegrini P; Contasta I; Russo T; Carolei A; Adorno D
Neuroimmunomodulation; 2005; 12(1):29-44. PubMed ID: 15756051
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cell-based cancer immunotherapies.
Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
[TBL] [Abstract][Full Text] [Related]
30. Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.
Foley R; Tozer R; Wan Y
Transfus Med Rev; 2001 Oct; 15(4):292-304. PubMed ID: 11668436
[TBL] [Abstract][Full Text] [Related]
31. Handbook of experimental pharmacology "dendritic cells": the use of dexamethasone in the induction of tolerogenic DCs.
van Kooten C; Stax AS; Woltman AM; Gelderman KA
Handb Exp Pharmacol; 2009; (188):233-49. PubMed ID: 19031029
[TBL] [Abstract][Full Text] [Related]
32. The role of dendritic cells in multiple sclerosis.
Wu GF; Laufer TM
Curr Neurol Neurosci Rep; 2007 May; 7(3):245-52. PubMed ID: 17488591
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of multiple sclerosis.
Weiner HL; Hafler DA
Ann Neurol; 1988 Mar; 23(3):211-22. PubMed ID: 3288084
[TBL] [Abstract][Full Text] [Related]
34. Targeting nanoparticles to dendritic cells for immunotherapy.
Cruz LJ; Tacken PJ; Rueda F; Domingo JC; Albericio F; Figdor CG
Methods Enzymol; 2012; 509():143-63. PubMed ID: 22568905
[TBL] [Abstract][Full Text] [Related]
35. The immunopathogenesis of multiple sclerosis.
Prat E; Martin R
J Rehabil Res Dev; 2002; 39(2):187-99. PubMed ID: 12051463
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cells as natural adjuvants.
Citterio S; Rescigno M; Foti M; Granucci F; Aggujaro D; Gasperi C; Matyszak MK; Girolomoni G; Ricciardi-Castagnoli P
Methods; 1999 Sep; 19(1):142-7. PubMed ID: 10525450
[TBL] [Abstract][Full Text] [Related]
37. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
Fujii S
Trends Immunol; 2008 May; 29(5):242-9. PubMed ID: 18372215
[TBL] [Abstract][Full Text] [Related]
38. Elevation of Sema4A implicates Th cell skewing and the efficacy of IFN-β therapy in multiple sclerosis.
Nakatsuji Y; Okuno T; Moriya M; Sugimoto T; Kinoshita M; Takamatsu H; Nojima S; Kimura T; Kang S; Ito D; Nakagawa Y; Toyofuku T; Takata K; Nakano M; Kubo M; Suzuki S; Matsui-Hasumi A; Uto-Konomi A; Ogata A; Mochizuki H; Sakoda S; Kumanogoh A
J Immunol; 2012 May; 188(10):4858-65. PubMed ID: 22491253
[TBL] [Abstract][Full Text] [Related]
39. Dendritic Cells in Sepsis: Pathological Alterations and Therapeutic Implications.
Wu DD; Li T; Ji XY
J Immunol Res; 2017; 2017():3591248. PubMed ID: 29075648
[TBL] [Abstract][Full Text] [Related]
40. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma.
Pajtasz-Piasecka E; Rossowska J; Duś D; Weber-Dabrowska B; Zabłocka A; Górski A
Immunol Lett; 2008 Feb; 116(1):24-32. PubMed ID: 18166233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
